SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Xenomics, Inc., a Florida corporation, on December 7, 2005, covering events occurring on December 1, 2005. The filing addresses changes to the Board of Directors. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Board Election: John Brancaccio was elected to the Board of Directors to serve until the next annual meeting of stockholders or until his successor is qualified.
- Board Resignation: Dr. Thomas Adams resigned from the Board of Directors for personal reasons.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document serves solely to disclose the departure and election of directors.
Key Facts for Investor Verification
- Verify the current composition of the Xenomics, Inc. Board of Directors following the resignation of Dr. Thomas Adams.
- Confirm the background and qualifications of the newly elected director, John Brancaccio, including his role at Accelerated Technologies, Inc.
- Review the referenced Press Release (Exhibit 99.1) dated December 6, 2005, for additional context on these governance changes.